The pharmacology of carvedilol (original) (raw)

Summary

Carvedilol is a potent antihypertensive agent with a dual mechanism of action. At relatively low concentrations it is a competitive β-adrenoceptor antagonist and a vasodilator, whereas at higher concentrations it is also a calcium channel antagonist. The antihypertensive activity of carvedilol is characterized by a decrease in peripheral vascular resistance, resulting from the vasodilator activity of the compound, with no reflex tachycardia, as a result of β-adrenoceptor blockade. The antihypertensive activity of carvedilol is associated with an apparent “renal sparing” effect in that the reduction in mean arterial blood pressure does not compromise renal blood flow or urinary sodium excretion. Studies on the mechanism of action of carvedilol indicate that the compound is a potent competitive antagonist of β1- and β2-adrenoceptors with a dissociation constant (KB) of 0.9 n_M_ at both β-adrenoceptor subtypes. Carvedilol is also a potent α1-adrenoceptor antagonist (KB = 11 n_M_), which accounts for most, if not all, of the vasodilating response produced by the compound. At concentrations above 1 μM, carvedilol is a calcium channel antagonist. This activity can be demonstrated in vivo at doses that represent the higher end of the anti-hypertensive dose-response curve. Although the calcium-channel blocking activity of carvedilol may not contribute to the antihypertensive activity of the compound, it may play a prominent role in certain peripheral vascular beds, such as the cutaneous circulation, where marked increases in blood flow are observed. The data indicate that carvedilol is an antihypertensive agent that is both a β-adrenoceptor antagonist and a vasodilator. The vasodilating activity of carvedilol results largely from α1-adrenoceptor blockade, and its β-adrenoceptor blocking activity prevents reflex tachycardia. In some regional vascular beds, such as the cutaneous circulation, the calcium-channel blocking activity of carvedilol may be responsible for increasing the blood flow.

Access this article

Log in via an institution

Subscribe and save

• Get 10 units per month
• Download Article/Chapter or eBook
• 1 Unit = 1 Article or 1 Chapter
• Cancel anytime Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

• Arunlakshana O, Schild HO (1959) Some quantitative uses of drug antagonism. Br J Pharmacol 14: 45–58
  Google Scholar
• Eggertsen R, Sivertsson R, Andren L, Hansson L (1987) Acute and long-term hemodynamic effects of carvedilol, a combined betaadrenoceptor blocking and precapillary vasodilating agent, in hypertensive patients. J Cardiovasc Pharmacol 10 [Suppl 11]: 97–100
  Google Scholar
• Nichols AJ, Ruffolo RR Jr (1988) The relationship of a-adrenoceptor reserve and agonist intrinsic efficacy to calcium utilization in the vasculature. Trends Pharmacol Sci 9: 236–241
  PubMed Google Scholar
• Rodeheffer RJ, Rommer JA, Wigley F, Smith CR (1983) Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomena. N Engl J Med 308: 880–883
  PubMed Google Scholar
• Ruffolo RR Jr (1982) Important concepts of receptor theory. J Auton Pharmacol 2: 277–295
  PubMed Google Scholar
• Ruffolo RR Jr (1984) Stereochemical requirements for activation and blockade of alpha-1 and alpha-2 adrenoceptors. Trends Pharmacol Sci 5: 160–164
  Google Scholar
• Ruffolo RR Jr (1987) The pharmacology of dobutamine. Am J Med Sci 294: 244–248
  PubMed Google Scholar
• Ruffolo RR Jr (1988) Cardiovascular adrenoceptors: physiology and critical care implications. In: Chernow B (ed) The pharmacologic approach to the critically ill patient. Williams and Wilkins, Baltimore, pp 166–183
  Google Scholar
• Seki N, Nagao T, Komori K, Suzuki H (1988) Alpha- and betaadrenoceptor blocking action of carvedilol in the canine mesenteric artery and vein. J Pharmacol Exp Ther 246: 1116–1122
  PubMed Google Scholar
• Smith CD, McKendry RJR (1982) Controlled trial of nifedipine in the treatment of Raynaud's phenomenon. Lancet II: 1299–1301
  Google Scholar
• Sponer G, Strein K, Muller-Beckmann B, Bartsch W (1987) Studies on the mode of vasodilating action of carvedilol. J Cardiovasc Pharmacol 10 [Suppl 11]: 42–48
  Google Scholar
• Strein K, Sponer G, Muller-Beckmann G, Bartsch W (1987) Pharmacological profile of carvedilol, a compound with beta-blocking and vasodilating properties. J Cardiovasc Pharmacol 10 [Suppl 11]: 33–41
  Google Scholar
• Sundberg S, Tiihonen K, Gordin A (1987) Vasodilatory effects of carvedilol and pindolol. J Cardiovas Pharmacol 10 [Suppl 11]: 76–80
  Google Scholar

Download references

Author information

Authors and Affiliations

1. Department of Pharmacology, L523 Smith Kline Beecham, p. l. c., 709 Swedeland Road, 19406-0939, King of Prussia, Pennsylvania, USA
   R. R. Ruffolo Jr Ph.D., M. Gellai, J. P. Hieble, R. N. Willette & A. J. Nichols

Authors

1. R. R. Ruffolo Jr Ph.D.
   You can also search for this author inPubMed Google Scholar
2. M. Gellai
   You can also search for this author inPubMed Google Scholar
3. J. P. Hieble
   You can also search for this author inPubMed Google Scholar
4. R. N. Willette
   You can also search for this author inPubMed Google Scholar
5. A. J. Nichols
   You can also search for this author inPubMed Google Scholar

Rights and permissions

About this article

Cite this article

Ruffolo, R.R., Gellai, M., Hieble, J.P. et al. The pharmacology of carvedilol.Eur J Clin Pharmacol 38 (Suppl 2), S82–S88 (1990). https://doi.org/10.1007/BF01409471

Download citation

• Issue Date: March 1990
• DOI: https://doi.org/10.1007/BF01409471

Key words